HEI3090

HEI3090 is a P2X7R activator. HEI3090 stimulates dendritic cells expressing P2X7R to produce IL-18, which subsequently promotes Natural Killer cells and CD4 T cells within tumors to produce IFN-γ, leading to a sustained antitumor response. HEI3090 can be used to enhance the efficacy of αPD-1 therapy in non-small cell lung cancer (NSCLC) [1].

Product Specifications

CAS Number

[2377167-56-9]

UNSPSC

12352005

Target

IFNAR; Interleukin Related; P2X Receptor

Type

Reference compound

Related Pathways

Immunology/Inflammation; Membrane Transporter/Ion Channel

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/hei3090.html

Purity

99.04

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

ClC1=NC=C(C=C1)NC(N2[C@@H](CCC2=O)C(NCC3=C(C=C(C=C3)Cl)Cl)=O)=O

Molecular Formula

C18H15Cl3N4O3

Molecular Weight

441.70

References & Citations

[1]Douguet L, et al. A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy. Nat Commun. 2021 Jan 28;12 (1) :653.